Catabasis Pharmaceuticals adds to two leadership team

Catabasis Pharmaceuticals' Andrew Nichols has been named the company’s new chief scientific officer and Angelika Fretzen has been named senior vice president of product development.

“Andy and Angelika have provided tremendous value to Catabasis in supporting the development of edasalonexent (CAT-1004) in Duchenne muscular dystrophy and also the advancement of our pipeline in rare diseases,” Catabasis CEO Jill Milne said. “We look forward to their further leadership of and contributions to Catabasis.”

Nichols has worked in drug development for more than 25 years. He has led in areas such as target discovery, translational research and early clinical development for companies in the field of pharmaceutical and biotechnology. He began work with Catabasis in 2014 and has served as the senior vice president of research and non-clinical development during his tenure with the company.

Fretzen brings with her more than 15 years of experience in entrepreneurial drug discovery and development. She has worked at Catabasis since 2014, where she has held the position of vice president of product development and program management. Before her time with Catabasis, Fretzen was with Ironwood Pharmaceuticals where she served as vice president of pharmaceutical chemistry and development.